Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer

APMIS

Volumn 120, Issue 12, 2012, Pages 1000-1007

  Hillig, Thore ^a   Thode, Jørgen ^a   Breinholt, Marie F ^b   Franzmann, Maria Benedicte ^b   Pedersen, Carsten ^c   Lund, Flemming ^a   Mygind, Henrik ^c   Sölétormos, György ^a   Rudnicki, Martin ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c Hospital South   (Denmark)

Author keywords

Diagnosis; Fluorescence in situ hybridization; HER2; Laser capture microdissection; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; TRASTUZUMAB;

ACCURACY; ADULT; ARTICLE; CANCER CELL; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LASER CAPTURE MICRODISSECTION; MEASUREMENT; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE FIXATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LASER CAPTURE MICRODISSECTION; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 84869082991     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02929.x     Document Type: Article

References (26)

1. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-82.
2. Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006;13:39-49.
3. Nathanson DR, Nash GM, Chen B, Gerald W, Paty PB. Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique. J Am Coll Surg 2003;197:419-25.
4. Erdogan S, Ergin M, Tuncer I. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors. Neoplasma 2003;50:326-30.
5. Wilson KS, Roberts H, Leek R, Harris AL, Geradts J. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol 2002;161:1171-85.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
7. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
8. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
9. Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 2011;122:116-20.
10. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90.
11. Frederick PJ, Straughn JM Jr, Alvarez RD, Buchsbaum DJ. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 2009;113:384-90.
12. Makino H, Uetake H, Danenberg K, Danenberg PV, Sugihara K. Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer. BMC Cancer 2008;8:210.
13. Tai CJ, Lo HY, Hsu CH, Tai CJ, Liu WM. Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy. Gynecol Oncol 2006;101:184-5.
14. Cadron I, Van Gorp T, Moerman P, Waelkens E, Vergote I. Proteomic analysis of laser microdissected ovarian cancer tissue with SELDI-TOF MS. Methods Mol Biol 2011;755:155-63.
15. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-33.
16. Egervari K, Toth J, Nemes Z, Szollosi Z. An alternative and reliable real-time quantitative PCR method to determine HER2/neu amplification in breast cancer. Appl Immunohistochem Mol Morphol 2009;17:247-54.
17. Bustin SA, editor. A-Z of Quantitative PCR, 5th edn. United States of America: International University Line, 2004.
18. Vermeij J, Teugels E, Bourgain C, Xiangming J, in 't Veld P, Ghislain V, et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008;8:3.
19. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P, Guastalla JP, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2007;2:e1138.
20. Lin CK, Lin WL, Chen FL, Lee MY, Kuo JF, Ruan A, et al. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization. Int J Gynecol Pathol 2011;30:372-9.
21. Lin WL, Kuo WH, Chen FL, Lee MY, Ruan A, Tyan YS, et al. Identification of the coexisting HER2 Gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Ann Surg Oncol 2011;18:2388-94.
22. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009;9:433.
23. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005;68:154-61.
24. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004;14:1086-96.
25. Scoles DR, Pavelka J, Cass I, Tran H, Baldwin RL, Armstrong K, et al. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecol Oncol 2007;104:120-8.
26. Bartlett JM, Campbell FM, Ibrahim M, Thomas J, Wencyk P, Ellis I, et al. A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH. Histopathology 2010;56:297-304.